NEW SUNSCREEN CONTAINING BISMUTHOXYCHLORIDE TO PROTECT AGAINST BLUE LIGHT
Patent Information
- Application Number
- DE502020009702
- Authority / Receiving Office
- DE · DE
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-10-01
- Filing Date
- 2020-09-01
- Publication Date
- 2024-11-21
- Estimated Expiration
- 2040-09-01
AI Technical Summary
Current sunscreens are inadequate in protecting against blue light radiation, which penetrates deeper into the skin and causes oxidative stress, damaging the epidermal barrier and leading to premature skin aging, and also damage other ingredients in the sunscreen.
A cosmetic sunscreen formulation combining bismuthoxychloride particles with a refractive index of 2.15 and titanium dioxide or zinc oxide, optimized with specific particle sizes and surface areas, to provide enhanced protection against blue light radiation.
The combination significantly improves protective performance against blue light radiation, safeguarding both the sunscreen and treated skin, thereby preventing premature aging and damage to other ingredients.
Description
[0001] The present invention relates to a cosmetic preparation containing a) bismuth oxychloride particles with a refractive index of 2.15 and b) titanium dioxide and / or zinc oxide with a primary particle size of 10 to 200 nm, as well as the use of a combination of a) bismuth oxychloride particles with a refractive index of 2.15 and b) titanium dioxide and / or zinc oxide with a primary particle size of 10 to 200 nm in cosmetic preparations for protection against radiation in the wavelength range of 401 to 500 nm.
[0002] The trend away from a refined pallor toward "healthy, athletic tan" has been unbroken for years. To achieve this, people expose their skin to sunlight, as this triggers pigment formation in the form of melanin. However, the ultraviolet radiation from sunlight also has a damaging effect on the skin. In addition to acute damage (sunburn), long-term damage such as an increased risk of skin cancer occurs with excessive exposure to light in the UVB range (wavelength: 280-320 nm). Excessive exposure to UVB and UVA radiation (wavelength: 320-400 nm) also leads to a weakening of the elastic and collagen fibers of the connective tissue. This leads to numerous phototoxic and photoallergic reactions and premature skin aging.
[0003] To protect the skin, a number of sunscreen filter substances have been developed that can be used in cosmetic preparations. These UVA and UVB filters are summarized in most industrialized countries in the form of positive lists, such as Annex 7 of the Cosmetics Regulation.
[0004] However, the large number of commercially available sunscreens should not obscure the fact that these state-of-the-art preparations have a number of disadvantages.
[0005] Cosmetic sunscreens typically contain filter substances that absorb and / or reflect electromagnetic radiation in the UV-A and UV-B wavelength range. Recently, so-called "blue light radiation," i.e., electromagnetic radiation in the wavelength range of 400 to 500 nm, has become the focus of research. It has been found that this blue light penetrates deeper into the skin than UV-A or UV-B radiation and therefore poses a threat to all skin layers. Blue light induces oxidative stress in the skin, both in reactive oxygen species (ROS) and reactive nitrogen species (RNS). It weakens the epidermal barrier and damages the extracellular matrix. Hyperpigmentation and the destruction of proteins and lipids can result.All of these effects can lead to premature skin aging, and based on these findings, it can also be assumed that the other ingredients in sunscreens (e.g. lipids, antioxidants) themselves are also damaged when exposed to blue light radiation.
[0006] It was therefore the object of the present invention to develop a cosmetic preparation (in particular a sunscreen) that protects against the damage caused by blue light radiation, whereby this protection includes both the sunscreen itself and the skin treated with it.
[0007] Surprisingly, the problem is solved by a cosmetic sunscreen according to claim 1.
[0008] Surprisingly, the object is further achieved by a combination according to claim 2.
[0009] Although the prior art knows CN 109 908 020 A, EP 2 813 264 A1, EP 3 103 433 A1, CN 109 077 952 A, KR 2019 0083832 A as well as the database entries in the GNPD database of Mintel with the entry numbers 2753779 (BB Cream All-in-1 Blemish), 2600009 (BB Cream All-in-1 Skin Perfector), 2176612 (BB Cream SPF 15), and 6908779 (Eraser Foam), these disclosures could not point the way to the present invention.
[0010] In the context of the present disclosure, the phrases "according to the invention", "preparation according to the invention" etc. always refer to the preparations and uses according to the invention, ie also to preparations in which the use according to the invention is realized.
[0011] Surprising and unforeseeable for the person skilled in the art was the significantly improved protective performance when titanium dioxide or zinc oxide was combined with the bismuth oxychloride according to the invention.
[0012] It has been found particularly preferred according to the invention for the bismuth oxychloride to have a specific surface area of 230-350m2 / kg. This is calculated according to the invention from the particle size (see below) and the density.
[0013] The bismuth oxychloride according to the invention is further characterized as being preferred according to the invention if its particle size is selected such that 10% by volume is less than 1-1.5 µm, 50% by volume is less than 3-6.5 µm, and 90% by volume is less than 8-15 µm. The particle size distribution is calculated according to the Mie theory model.
[0014] It is preferred according to the invention if the bulk density of the bismuth oxychloride is 7.70-7.75 g / cm 3< and particularly preferably 7.72 g / cm 3<.
[0015] All values for bismuth oxychloride are determined in the dry state.
[0016] The bismuth oxychloride according to the invention can be purchased, for example, from Merck under the trade name RonaFlair ESQ, Art. No. 117061, or from Textron under the trade name Evoshield.
[0017] According to the invention, it is advantageous if the preparation contains bismuth oxychloride in a concentration of 0.1 to 10% by weight, based on the total weight of the preparation. A concentration of 1 to 5.0% by weight, based on the total weight of the preparation, is preferred according to the invention.
[0018] The titanium dioxide used is advantageous according to the invention and has the crystal structure rutile and a primary particle size of 2-100 nm.
[0019] It is preferred according to the invention if the primary particle size of the titanium dioxide according to the invention is in the range between 5 and 50 nm.
[0020] Advantageous embodiments of the present invention are characterized in that the titanium dioxide is coated with silica (silicon dioxide and / or silicic acid).
[0021] According to the invention, it is preferred if the silica-coated titanium dioxide has a layer of dimethicone, simethicone, or methicone on the outer side of the silica layer (i.e., on the side facing away from the titanium dioxide). Among these substances, dimethicone is particularly preferred according to the invention.
[0022] According to the invention, it is advantageous if the secondary particle size of the titanium dioxide in the rutile crystal structure with a primary particle size of 2-100 nm is between 0.05 and 50 µm. The range from 0.1 to 1 µm is preferred according to the invention.
[0023] The expert can obtain the primary and secondary particle size from the following literature: SCCS / 1516 / 13 Opinion on Titanium Dioxide (nano form) Colipa No. S75 of the Cosmetics Europe Personal Care Association. Corresponding publications also exist on the primary particle size of zinc oxide (SCCS / 1489 / 12 Opinion).
[0024] Zinc oxide particles with a primary particle size of less than 150 nm are preferred. According to the invention, it is advantageously coated with triethoxycaprylylsilane.
[0025] It is advantageous according to the invention if the titanium dioxide and / or zinc oxide is contained in the preparation in a total amount of 1 to 30% by weight, based on the total weight of the preparation.
[0026] There are three embodiments of the invention: i) preparations containing bismuth oxychloride and b) Titanium dioxide.
[0027] In this case, the advantageous use concentrations according to the invention for the bismuth oxychloride are from 0.1 to 10% by weight and for titanium dioxide from 0.5 to 25% by weight, each based on the total weight of the preparation.
[0028] ii) preparations containing bismuth oxychloride and b) zinc oxide.
[0029] In this case, the advantageous use concentrations according to the invention for bismuth oxychloride are from 0.1 to 10% by weight and for zinc oxide from 0.5 to 25% by weight, each based on the total weight of the preparation.
[0030] iii) preparations containing bismuth oxychloride and b) titanium dioxide and zinc oxide.
[0031] In this case, the advantageous use concentrations according to the invention for bismuth oxychloride are from 0.1 to 10% by weight, for titanium dioxide from 0.5 to 10% by weight, and for zinc oxide from 0.5 to 20% by weight, in each case based on the total weight of the preparation.
[0032] Advantageous embodiments of the present invention are characterized in that the preparation additionally contains interference pigments. These can advantageously be used in a concentration of 0.5 to 6% by weight, based on the total weight of the preparation.
[0033] Interference pigments are effect pigments whose effect is based primarily or entirely on the interference of light on thin, highly refractive layers. They are characterized by the fact that they produce an angle-dependent color impression, known as a hue flop.
[0034] The following can be used as interference pigments preferred according to the invention: Titanium Dioxide (and) Mica (and) Tin Oxide; Mica (and) Titanium Dioxide (and) Silica; Calcium Sodium Borosilicate (and) Silica (and) Titanium Dioxide CI 77891; Cl 77891 (Titanium Dioxide) (and) Mica (and) Tin Oxide; Mica (and) Titanium Dioxide (and) Silica (and) Tin Oxide; Calcium Sodium Borosilicate (and) Titanium Dioxide (and) Tin Oxide; Calcium Aluminum Borosilicate (and) Titandium Dioxide; Mica (and) Titanium Dioxide
[0035] Furthermore, it is advantageous according to the invention if the preparation contains 2,2'-methylene-bis-(6-(2H-benzotriazol-2-yl)-4-(1,1,3,3-tetramethylbutyl)-phenol) (INCI: Methylene Bis-Benzotriazolyl Tetramethylbutylphenol) and / or 2,4,6-tris-(biphenyl)-1,3,5-triazine (INCI: Tris-Biphenyl Triazine).
[0036] It is advantageous according to the invention if the preparation contains one or more UV filters which are selected from the group of the compounds 2-phenylbenzimidazole-5-sulfonic acid and / or salts thereof; phenylene-1,4-bis-(2-benzimidazyl)-3,3'-5,5'-tetrasulfonic acid salts; 1,4-di(2-oxo-10-sulfo-3-bornylidenemethyl)-benzene and salts thereof; 4-(2-oxo-3-bornylidenemethyl)-benzenesulfonic acid salts; 2-methyl-5-(2-oxo-3-bornylidenemethyl)sulfonic acid salts; 2-(2H-benzotriazol-2-yl)-4-methyl-6-[2-methyl-3-[1,3,3,3-tetramethyl-1-[(trimethylsilyl)oxy]disiloxanyl]propyl]-phenol; 3-benzylidenecamphor; Ethylhexyl salicylate; terephthalidenedicamphersulfonic acid and / or its salts; 4-(dimethylamino)benzoic acid (2-ethylhexyl) ester; 2-ethylhexyl 2-cyano-3,3-diphenylacrylate (octocrylene), 4-(dimethylamino)benzoic acid amyl ester; 4-methoxybenzalmalonic acid di(2-ethylhexyl) ester; 2-hydroxy-4-methoxy-4'-methylbenzophenone; 2,2'-dihydroxy-4-methoxybenzophenone; homomenthyl salicylate (homosalate);2-Ethylhexyl-2-hydroxybenzoat; Dimethicodiethylbenzalmalonat; 3-(4-(2,2-bis Ethoxycarbonylvinyl)-phe-noxy)propenyl)-methoxysiloxan / Dimethylsiloxan - Copolymer; 4-(tert.-Butyl)-4'-methoxydiben-zoylmethan; Dioctylbutylamidotriazon (INCI: Diethylhexyl-Butamidotriazone); 2,4-bis-[5-1(dimethylpropyl)benzoxazol-2-yl-(4-phenyl)-imino]-6-(2-ethylhexyl)-imino-1,3,5-triazin mit der (CAS Nr. 288254-16-0); 2,4-Bis-{[4-(2-ethyl-hexyloxy)-2-hydroxy]-phenyl}-6-(4-methoxyphenyl)-1,3,5-triazin (INCI: Bis-Ethylhexyloxyphenol Methoxyphenyl Triazin); 4,4',4"-(1,3,5-Triazin-2,4,6-triyltriimino)-tris-benzoesäure-tris(2-ethylhexylester) (auch: 2,4,6-Tris-[anilino-(p-carbo-2'-ethyl-1'-hexyloxy)]-1,3,5-triazin (INCI: Ethylhexyl Triazone); Merocyanine.;
[0037] According to the invention, the use of 2,4,6-tris-[anilino-(p-carbo-2'-ethyl-1'-hexyloxy)]-1,3,5-triazine (INCI: Ethylhexyl Triazone), 2,4-bis-{[4-(2-ethyl-hexyloxy)-2-hydroxy]-phenyl}-6-(4-methoxyphenyl)-1,3,5-triazine (INCI: Bis-Ethylhexyloxyphenol methoxyphenyl Triazine), 2-ethylhexyl 2-hydroxybenzoate (INCI: Ethylhexyl Salicylate) and 2-phenylbenzimidazole-5-sulfonic acid salts is preferred.
[0038] Advantageous embodiments of the present invention are characterized in that the preparation is in the form of an alcoholic solution or an emulsion.
[0039] According to the invention, it is preferred if the preparation is in the form of an emulsion and particularly preferably in the form of an O / W emulsion.
[0040] If the preparation according to the invention is in the form of an O / W emulsion, it is advantageously characterized according to the invention in that the preparation contains one or more O / W emulsifiers selected from the group of the compounds glyceryl stearate citrate, glyceryl stearate (self-emulsifying), stearic acid, stearate salts, polyglyceryl-3-methylglycose distearate, sodium cetearyl sulfate, potassium cetyl phosphate, polyglyceryl-10 stearate, sodium stearoyl glutamate.
[0041] These O / W emulsifiers according to the invention can advantageously be contained in the preparation in a concentration of 0.001 to 10% by weight and preferably in a concentration of 0.1 to 7% by weight, based on the total weight of the preparation.
[0042] According to the invention, it is preferred if the preparation contains sodium stearoylglutamate as an emulsifier.
[0043] It is further advantageous according to the invention if the preparation contains cetyl alcohol, stearyl alcohol and / or glyceryl stearate.
[0044] According to the invention, it is advantageous for the combination if the preparation according to the invention is free from polyethylene glycol, polyethylene glycol ethers and polyethylene glycol esters (so-called PEG derivatives).
[0045] Advantageous embodiments of the combination according to the invention are further characterized in that the preparation does not contain 3-(4-methylbenzylidene)-camphor, 2-hydroxy-4-methoxybenzophenone (INCI: oxybenzone), 2-ethylhexyl 4-methoxycinnamate, isoamyl 4-methoxycinnamate and ethylhexyl 2-cyano-3,3-diphenylacrylate (INCI: octocrylene), parabens, methylisothiazolinone, chlorphenesin, chloromethylisothiazolinone and DMDM hydantoin.
[0046] It is furthermore advantageous within the meaning of the present invention if the preparation contains spherical, hollow silica particles with an average particle diameter of 15 to 20 µm, measured by scanning electron microscopy.
[0047] It is furthermore particularly advantageous according to the invention if the preparation according to the invention contains hexyl 2-[4-(diethylamino)-2-hydroxybenzoyl]benzoate (INCI: Diethylamino hydroxybenzoyl hexyl benzoate) and / or 4-(tert-butyl)-4'-methoxydibenzoylmethane.
[0048] Advantageous embodiments of the present invention are further characterized in that the preparation contains one or more alkanediols from the group of the compounds 1,2-pentanediol, 1,2-hexanediol, 1,2-octanediol, 1,2-decanediol, 2-methyl-1,3-propanediol, ethylhexylglycerol and / or 4-hydroxyacetophenone.
[0049] Furthermore, it is advantageous according to the invention if the preparation contains tapioca starch and / or silica dimethyl silylate.
[0050] Last but not least, the advantageous embodiments according to the invention are characterized in that the preparation contains one or more compounds selected from the group of the compounds limonene, citral, linalool, alpha-isomethyl ionone, geraniol, citronellol, 2-isobutyl-4-hydroxy-4-methyltetrahydropyran, 2-tert-pentylcyclohexyl acetate, 3-methyl-5-phenyl-1-pentanol, 7-acetyl-1,1,3,4,4,6-hexamethyltetralin, adipic acid diester, alpha-amyl cinnamaldehyde, alpha-methyl ionone, amyl C butylphenyl methylpropional cinnamal, amyl salicylate, amyl cinnamyl alcohol, anise alcohol, benzoin, benzyl alcohol, benzyl benzoate, benzyl cinnamate, benzyl salicylate, bergamot oil, bitter orange oil, butylphenyl methylpropional, cardamom oil, cedrol, cinnamal, Cinnamyl Alcohol, Citronellyl Methyl Crotonate, Citron Oil, Coumarin, Diethyl Succinate, Ethyllinalool, Eugenol, Ethylene Brassylate, Evernia Furfuracea Extract,
[0051] Contains Evernia Prunastri Extract, Farnesol, Guaiac Wood Oil, Hexyl Cinnamal, Hexyl Salicylate, Hydroxycitronellal, Lavender Oil, Lemon Oil, Linalool Acetate, Mandarin Oil, Menthyl PCA, Methylheptenone, Nutmeg Oil, Rosemary Oil, Sweet Orange Oil, Terpineol, Tonka Bean Oil, Triethyl Citrate and / or Vanillin.
[0052] The preparation according to the invention can also be composed like a conventional cosmetic sunscreen. It has proven advantageous if the preparation contains one or more humectants.
[0053] The preparation according to the invention can advantageously contain humectants. Humectants are substances or mixtures of substances which give cosmetic preparations the property of inhibiting the release of moisture from the horny layer (also called t rans eepidermal water loss (TEWL)) and / or to positively influence the hydration of the stratum corneum.
[0054] Advantageous humectants (moisturizers) within the meaning of the present invention are, for example, glycerin, lactic acid and / or lactates, in particular sodium lactate, butylene glycol, propylene glycol, biosaccharide gum-1, glycine soya, ethylhexyloxyglycerin, pyrrolidonecarboxylic acid and urea. Furthermore, it is particularly advantageous to use polymeric moisturizers from the group of water-soluble and / or water-swellable and / or water-gellatable polysaccharides. Particularly advantageous are, for example, hyaluronic acid, chitosan and / or a fucose-rich polysaccharide which is filed in Chemical Abstracts under the registration number 178463-23-5 and is available, for example, under the name Fucogel®< 1000 from SOLABIA SA. Moisturizers can also be used advantageously as anti-wrinkle active ingredients to protect against skin changes, such as those caused by, for example, acne. B. occur in skin aging.
[0055] Advantageous embodiments of the present invention are characterized in that the preparation contains one or more oils selected from the group of the compounds butylene glycol dicaprylate / dicaprate, phenethyl benzoate, C12-15 alkyl benzoate, dibutyl adipate; diisopropyl sebacate, dicaprylyl carbonate, di-C12-13 alkyl tartrate, butyloctyl salicylate, diethylhexyl syringylidene malonate, hydratenated castor oil dimerate, triheptanoin, C12-13 alkyl lactate, C16-17 alkyl benzoate, propylheptyl caprylate, caprylic / capric triglyceride, diethylhexyl 2,6-naphthalate, octyldodecanol, caprylic / capric triglyceride, ethylhexyl cocoate, isopropyl palmitate.
[0056] According to the invention, it is preferred if the preparation contains dibutyl adipate, butylene glycol dicaprylate / dicaprate and / or C12-C15 alkyl benzoate.
[0057] The aqueous phase of the preparations according to the invention can advantageously contain conventional cosmetic auxiliaries, such as, for example, alcohols, in particular those with a low carbon number, preferably ethanol and / or isopropanol, or polyols with a low carbon number and their ethers, preferably propylene glycol, glycerin, electrolytes, self-tanning agents and, in particular, one or more thickeners, which can advantageously be selected from the group consisting of silicon dioxide, aluminum silicates, polysaccharides or their derivatives, e.g., hyaluronic acid, xanthan gum, hydroxypropylmethylcellulose, etc.
[0058] Advantageous embodiments of the present invention are characterized in that the preparation contains one or more compounds selected from the group of alpha-lipoic acid, folic acid, phytoene, D-biotin, coenzyme Q10, alpha-glucosylrutin, carnitine, carnosine, natural and / or synthetic isoflavonoids, flavonoids, creatine, creatinine, taurine, β-alanine, panthenol, magnolol, honokiol, tocopheryl acetate, dihydroxyacetone; 8-hexadecene-1,16-dicarboxylic acid, glyceryl glycose, (2-hydroxyethyl)urea, vitamin E or its derivatives, hyaluronic acid and / or its salts and / or licochalcone A. Vergleichsversuch
[0059] The following formulations were prepared and the protection against blue light was determined using the following method.
[0060] Measurement of blue light protection according to ISO 24443.
[0061] Each product was applied on 3 WW5 PMMA plates (1.3 mg / cm2< + / - 1.5%) with the following application characteristics: two-phase, Phase A: Light pressure and circular movement, Phase B: Pressure higher than 150 g and strokes on four different directions, fingers covered with a finger cot.
[0062] After equilibration after 30 min at 40 °C, transmittance was measured at three points per plate (280–600 nm in 1 nm increments). A plate coated with glycerol served as a 100% reference.
[0063] Material used: Plexiglass ®< WW5 (Schönberg GmbH & Co. KG, Germany) Measuring instrument: UV / VIS spectrometer Lambda 650 S (PerkinElmer) equipped with a 150 mm integrated sphere.
[0064] RonaFlair ESQ, Art. No. 117061 from Merck or Evoshield from Textron were used as bismuth oxychloride. inci _hevl_96 _hevl_161 _hevl_165 _hevl_171 Bismuth Oxychloride (Ronaflair ESQ) 0 5 2.5 2.5 Ethylhexylglycerin 0.25 0.25 0.25 0.25 Dibutyl Adipate 3 3 3 3 C12-15 Alkyl Benzoate 5 5 5 5 Butylene Glycol Dicaprylate / Dicaprate 4 4 4 4 Glyceryl Stearate 1 1 1 1 Sodium Stearoyl Glutamate 0.3 0.3 0.3 0.3 Parfum 0.3 0.3 0.3 0 Parfum 0 0 0 0.5 Glycerin 8.6 8.6 8.6 8.6 Aqua + Sodium Hydroxide 0.33 0.33 0.33 0.33 Phenoxyethanol 0.5 0.5 0.5 0.5 Stearyl Alcohol 1 1 1 1 Acrylates / C10-30 Alkyl Acrylate Crosspolymer 0.1 0.1 0.1 0.1 Xanthan Gum 0.4 0.4 0.4 0.4 Aqua 56.47 51.47 48.97 43.77 Alcohol Denat. + Aqua 6 6 6 6 Aqua + Trisodium EDTA 1 1 1 1 Ethylhexyl Salicylate 4 4 4 4 Bis-Ethylhexyloxyphenol Methoxyphenyl Triazine 1.75 1.75 1.75 1.75 Ethylhexyl Triazone 1.5 1.5 1.5 1.5 Butyl Methoxydibenzoylmethane 3.5 3.5 3.5 3.5 Phenylbenzimidazole Sulfonic Acid 1 1 1 1 Titanium Dioxide (nano) + Silica + Dimethicone 0 0 5 0 Methylene Bis-Benzotriazolyl Tetramethylbutylphenol 0 0 0 10 Transmission in % [400-500 nm] 97,79 % 82,04 % 69,72 % 71,82 % Beispiele
[0065] The following examples are intended to illustrate the present invention without limiting it. Unless otherwise stated, all quantities, proportions, and percentages are based on the weight and the total amount or the total weight of the preparations. Beispiele 1 2 3 4 5 6 7 8 9 10 11 12 INCI m[% ] m[% ] m[% ] m[% ] m[% ] m[% ] m[% ] m[% ] m[%] m[% ] m[% ] m[% ] Ronaflair ESQ 2,5 5 5 2 6 3 Evoshield 2,5 5 2 6 3 3 VP / Hexadecene Copolymer 0,5 1 1 0,5 1 0,5 Tocopherylacetate 0,06 0,1 0,1 0,01 0,15 0,06 0,5 0,1 0,06 0,15 0,1 0,1 Panthenol 1 1,4 1,4 0,5 0,5 1 1 0,5 0,5 Ethylhexylglycerin 0,3 0,5 0,5 0,25 0,3 0,25 0,25 1,2-Hexandiole 0,4 1 1 Methylpropanediole 0,2 0,2 C12-15 Alkylbenzoate 4,5 6 6 3 6 7 7,5 Caprylic / Capric Triglycerides 4 4 2 3 Isopropyl Palmitate 4 3 3 3 Dimethicone 2 1 0,5 Octyldodecanol 2 2 Ethylhexyl Cocoate 1 2 3 3 Myristyl Myristate 2 1 1 1,5 1 Cetearyl Alcohol 1 1,5 1 1 Hydrogenated Coco-Glycerides 5 2 1 1 Butylene Glycol Dicaprylate / Dicaprate 1 3 1,5 2 Dicaprylyl Carbonate 1 3 3 1,5 C18-38 Alkyl Hydroxystearoyl Stearate 0,5 Polyglyceryl-3 Methylglucose Distearate 0,15 0,15 Glyceryl Stearate Citrate 2 3 3 2 2 Glyceryl Stearate 1 1 Sodium Stearoyl Glutamate 0,5 Glyceryl Stearate SE 1 1 1 Sodium Cetearal Sulfate 0,15 0,15 0,15 0,15 Silica dimethyl Silylate 0,5 0,5 0,5 0,3 1 0,5 1 Tapioca starch 3 3 Parfum 0,4 0,3 0,3 0,2 0,4 0,4 0,5 0,3 0,2 0,2 Glycerin 6 8 8 5 1 1 5 8 6 5 1 1 Citric Acid 0,07 0,09 0,09 0,01 0,00 8 Sodium Citrate 0,16 0,15 0,15 0,16 0,17 Sodium Hydroxide 0,05 0,08 0,08 0,07 0,08 0,05 0,03 0,07 0,06 0,03 0,03 Phenoxyethanol 0,3 0,5 0,5 0,3 0,4 0,5 0,2 0,5 0,3 0,4 0,4 Methylparaben 0,2 0,3 0,3 0,2 0,2 0,3 0,4 0,2 0,3 0,3 Ethylparaben 0,2 0,3 0,3 0,2 0,3 0,2 0,3 Stearyl Alcohol 0,8 0,8 0,8 1 0,8 1,5 Interference Pigment 5 5 5 Silica 2 5 5 Acrylates / C10-30Alkyl Acrylates Crosspolymer 0,1 0,15 0,15 0,05 0,2 0,1 0,05 0,15 0,2 0,2 Carbomer 0,15 Hydroxyethylcellulose 0,1 Xanthan Gum 0,3 0,2 0,2 0,5 0,4 0,3 0,4 0,2 0,3 0,3 0,3 Cetyl Alcohol 0,5 1 1 2 Alcohol Denat 4 6 6 4 8 10 4 6 6 8 10 10 Trisodium EDTA 1 0,5 0,5 1 1 1 0,5 0,5 1 1 1 1 Homosalate 9 9 9 9,5 9 9 9 9 9 9 Octocrylene 9 9 9 9,5 8 8 Ethylhexyl Salicylate 4,5 4,75 4,75 4,75 4,75 4,75 4,75 4,75 4,75 4,75 Butyl Methoxydibebzoylmethan e 4,5 4,5 4,5 4,75 4,75 4,75 4,5 4,5 4,75 4,75 4,75 Methylene Bis-Benzotriazolyl Tetramethylbutylphenol 3 Titanium dioxide 3 6 1 2 1 1 1 3,5 2 Zinc Oxide 6 1 1 2 1 1 5 Bis-Ethylhexyloxyphenol Methoxyphenyl Triazine 3 3 4 4 3,5 4 4 3,5 3 4 4 Ethylhexyl Triazone 3 3 3 3 3 Diethylamino Hydroxybenzoyl Hexylbenzoate 8 Polysilicone-15 1 1 Phenylbenzimidazole Sulfonic Acid 1 1 1 1 1,5 1,5 1 0,5 Aqua ad 100 ad 100 ad 100 ad 100 ad 100 ad 100 ad 100 ad 100 ad 100 ad 100 ad 100 ad 100
[0066] RonaFlair ESQ, Art. No. 117061 from Merck or Evoshield from Textron were used as bismuth oxychloride.
Claims
1. Cosmetic sunscreen comprising a) bismuth oxychloride particles having a refractive index of 2.15 and b) titanium dioxide and / or zinc oxide having a primary particle size of 10 to 200 nm, characterized in that the composition is free of polyethylene glycol, polyethylene glycol ethers and polyethylene glycol esters (called PEG derivatives) and does not contain any 3-(4-methylbenzylidene)camphor, 2-hydroxy-4-methoxybenzophenone (INCI: Oxybenzone), 2-ethylhexyl 4-methoxycinnamate, isoamyl 4-methoxycinnamate and ethylhexyl 2-cyano-3,3-diphenylacrylate (INCI: Octocrylene), any parabens, methylisothiazolinone, chlorphenesin, chloromethylisothiazolinone and DMDM hydantoin.
2. Combination of a) bismuth oxychloride particles having a refractive index of 2.15 and b) titanium dioxide and / or zinc oxide having a primary particle size of 10 to 200 nm in cosmetic preparations for use for the protection against radiation in the wavelength range of 401 to 500 nm.
3. Cosmetic preparation according to Claim 1 or combination according to Claim 2, characterized in that the bismuth oxychloride has a specific surface area of 230-350 m2 / kg.
4. Cosmetic preparation or combination according to any of the preceding claims, characterized in that the bulk density of the bismuth oxychloride is 7.70-7.75 g / cm3.
5. Cosmetic preparation or combination according to any of the preceding claims, characterized in that the preparation the bismuth oxychloride is present in the preparation at a concentration of 0.1% to 10% by weight, based on the total weight of said preparation.
6. Cosmetic preparation or combination according to any of the preceding claims, characterized in that titanium dioxide and / or zinc oxide are / is present in the preparation in a total amount of 1% to 30% by weight, based on the total weight of said preparation.
7. Cosmetic preparation or combination according to any of the preceding claims, characterized in that the preparation additionally comprises interference pigments.
8. Cosmetic preparation or combination according to any of the preceding claims, characterized in that the preparation comprises 2,2'-methylenebis(6-(2H-benzotriazol-2-yl)-4-(1,1,3,3-tetramethylbutyl)-phenol) (INCI: Methylene Bis-Benzotriazolyl Tetramethylbutylphenol) and / or 2,4,6-tris(biphenyl)-1,3,5-triazine (INCI: Tris-Biphenyl Triazine).
9. Cosmetic preparation or combination according to any of the preceding claims, characterized in that the preparation comprises one or more UV filters selected from the following group of compounds: 2-phenylbenzimidazole-5-sulfonic acid and / or salts thereof; phenylene-1,4-bis(2-benzimidazyl)-3,3'-5,5'-tetrasulfonic acid salts; 1,4-di(2-oxo-10-sulfo-3-bornylidenemethyl)benzene and salts thereof; 4-(2-oxo-3-bornylidenemethyl)benzenesulfonic acid salts; 2-methyl-5-(2-oxo-3-bornylidenemethyl)-sulfonic acid salts; 2-(2H-benzotriazol-2-yl)-4-methyl-6-[2-methyl-3-[1,3,3,3-tetramethyl-1-[(trimethylsilyl)oxy]disiloxanyl]propyl]phenol; 3-benzylidenecamphor; ethylhexyl salicylate; terephthalidenedicamphorsulfonic acid and / or salts thereof; 2-ethylhexyl 4-(dimethylamino)benzoate; 2-ethylhexyl 2-cyano-3,3-diphenylacrylate (Octocrylene), amyl 4-(dimethylamino)benzoate; di(2-ethylhexyl) 4-methoxybenzalmalonate; 2-hydroxy-4-methoxy-4'-methylbenzophenone; 2,2'-dihydroxy-4-methoxybenzophenone; homomenthyl salicylate (Homosalate); 2-ethylhexyl 2-hydroxybenzoate; dimethicodiethylbenzalmalonate; 3-(4-(2,2-bisethoxycarbonylvinyl)phenoxy)propenyl)methoxysiloxane / dimethylsiloxane copolymer; 4-(tert-butyl)-4'-methoxydibenzoylmethane; dioctylbutylamido-triazone (INCI: Diethylhexyl Butamido Triazone); 2,4-bis[5-1(dimethylpropyl)benzoxazol-2-yl-(4-phenyl)imino]-6-(2-ethylhexyl)imino-1,3,5-triazine with (CAS No. 288254-16-0); 2,4-bis{[4-(2-ethylhexyloxy)-2-hydroxy]phenyl}-6-(4-methoxyphenyl)-1,3,5-triazine (INCI: Bis-Ethylhexyloxyphenol Methoxyphenyl Triazine); tris(2-ethylhexyl) 4,4',4"-(1,3,5-triazine-2,4,6-triyltriimino)trisbenzoate (also: 2,4,6-tris[anilino-(p-carbo-2'-ethyl-1'-hexyloxy)]-1,3,5-triazine (INCI: Ethylhexyl Triazone); merocyanines.
10. Cosmetic preparation or combination according to any of the preceding claims, characterized in that the preparation is in the form of an alcoholic solution or an emulsion.
11. Combination according to any of the preceding claims, characterized in that the preparation is free of polyethylene glycol, polyethylene glycol ethers and polyethylene glycol esters (called PEG derivatives).
12. Combination according to any of the preceding claims, characterized in that the preparation does not comprise any 3-(4-methylbenzylidene)camphor, 2-hydroxy-4-methoxybenzophenone (INCI: Oxybenzone), 2-ethylhexyl 4-methoxycinnamate, isoamyl 4-methoxycinnamate and ethylhexyl 2-cyano-3,3-diphenylacrylate (INCI: Octocrylene), any parabens, methylisothiazolinone, chlorphenesin, chloromethylisothiazolinone or DMDM hydantoin.
13. Cosmetic preparation or combination according to any of the preceding claims, characterized in that the preparation comprises spherical, hollow silica particles having an average particle diameter of 15 to 20 µm, measured by means of scanning electron microscopy.
14. Cosmetic preparation or combination according to any of the preceding claims, characterized in that the preparation comprises hexyl 2-[4-(diethylamino)-2-hydroxybenzoyl]benzoate (INCI: Diethylamino Hydroxybenzoyl Hexyl Benzoate) and / or 4-(tert-butyl)-4'-methoxydibenzoylmethane.
15. Cosmetic preparation or combination according to any of the preceding claims, characterized in that the preparation comprises one or more alkanediols from the following group of compounds: pentane-1,2-diol, hexane-1,2-diol, octane-1,2-diol, decane-1,2-diol, 2-methylpropane-1,3-diol, ethylhexylglycerin and / or 4-hydroxyacetophenone.
16. Cosmetic preparation or combination according to any of the preceding claims, characterized in that the preparation comprises tapioca starch and / or Silica Dimethyl Silyate.
17. Cosmetic preparation or combination according to any of the preceding claims, characterized in that the preparation comprises one or more compounds selected from the following group of compounds: limonene, citral, linalool, alpha-isomethylionone, geraniol, citronellol, 2-isobutyl-4-hydroxy-4-methyltetrahydropyran, 2-tert-pentylcyclohexyl acetate, 3-methyl-5-phenyl-1-pentanol, 7-acetyl-1,1,3,4,4,6-hexamethyltetralin, adipic acid diesters, alpha-amylcinnamaldehyde, alpha-methylionone, amyl C, butylphenyl methylpropional cinnamal, amyl salicylate, amylcinnamyl alcohol, anise alcohol, benzoin, benzyl alcohol, benzyl benzoate, benzyl cinnamate, benzyl salicylate, bergamot oil, bitter orange oil, butylphenyl methylpropional, cardamom oil, cedrol, cinnamal, cinnamyl alcohol, citronellyl methylcrotonate, lemon oil, coumarin, diethyl succinate, ethyl linalool, eugenol, ethylene brassylate, Evernia furfuracea extract, Evernia prunastri extract, farnesol, guaiac wood oil, hexyl cinnamal, hexyl salicylate, hydroxycitronellal, lavender oil, lime oil, linalyl acetate, mandarin oil, menthyl PCA, methylheptenone, nutmeg oil, rosemary oil, sweet orange oil, terpineol, tonka bean oil, triethyl citrate and / or vanillin.
